I rise today in support of the Food and Drug Administration Safety and Innovation Act, which is pending before the Senate this week. This legislation will give the FDA, through five agreements made between the agency and industry, the resources to approve additional drugs and devices every year for their safe and effective use. Without these agreements, the FDA, starting in October, would lack these resources which are necessary to approve new drugs and devices, and they would also lack resources to monitor the safety and efficacy of those drugs already on the market. This would result in a reversal of decades of work modernizing our drug and device approval and safety programs. I am particularly pleased that for the first time, the generic pharmaceutical industry will provide the agency with $1.5 billion over 5 years for faster product reviews. In fact, the essence of the legislation is that the industry is actually providing resources for the monitoring and for the approval of drugs. Getting generic drugs onto the market sooner will help lower costs for individuals and families as well as for the Federal and State governments.…
Share
More from Jack Reed
If the White House truly believed that these are terrorist organizations and the Defense Secretary truly thinks Tren de Aragua compares to al-Qaida, the administration should come to Congress and request a AUMF.
The Trump Administration is driving up energy prices and throttling back federal aid.
No, I will not yield. By the way, these mandates and requirements would be effective immediately, meaning they must be implemented for the 2026 election, which, I should point out, is already underway. There are primaries that have been…
At a moment when U.S. forces are building up across the Caribbean and tensions with Venezuela are at a boiling point, the departure of our top military commander in the region sends an alarming signal of instability within the chain of…





